Canton, MA, United States
Canton, MA, United States

Time filter

Source Type

Sarasota, FL, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Global Advanced Wound Care Management Market by Product type (advanced wound dressings (foam dressings, hydrocolloid dressings, Hydrofiber dressings, film dressings, alginate dressings, hydrogel dressings, collagen dressings), active wound care (artificial skin and skin substitutes, growth factors) and antimicrobial dressings) for Chronic and Acute wounds: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022”. According to the report, global demand for the advanced wound care management market was valued at approximately USD 10.9 billion in 2016 and is expected to generate revenue of around USD 15.8 billion by end of 2022, growing at a CAGR of around 6.4% between 2017 and 2022. Browse through 29 Market Tables and 26 Figures spread through 110 Pages and in-depth TOC on “Global Advanced Wound Care Management Market: Type, Size, Share, Statistics, Trends, Analysis, Segment and Forecast 2016 – 2022”. The Wound Healing Society defines a chronic wound as a wound that fails to progress through a normal, orderly, and timely sequence of repair or passes through the repair process without restoring anatomic and functional results.  Standard wound care therapy is ineffective in treating chronic and complex wounds and additional treatment modalities need to be applied. Since chronic wounds are very painful and can lead to severe complications such as amputation and depression, advanced wound care management plays important role in treating chronic wounds. Global advanced wound care management market is primarily driven by increased incidences of chronic diseases such as diabetes across the world. Other major driving factors are a rise in aging population, advancement in technologies and rise in a number of surgical procedures. However, high treatment cost and reluctance to accept the newer therapies may limit the growth of the market. Increasing focus on the need for rapid healing along with wide arena of vast product range in wound care management is expected to act as an opportunity for advanced wound care management market in near future. Browse the full "Global Advanced Wound Care Management Market by Product type (advanced wound dressings (foam dressings, hydrocolloid dressings, Hydrofiber dressings, film dressings, alginate dressings, hydrogel dressings, collagen dressings), active wound care (artificial skin and skin substitutes, growth factors) and antimicrobial dressings) for Chronic and Acute wounds: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022" report at https://www.zionmarketresearch.com/report/global-advanced-wound-care-management-market Advanced wound care management market is segmented into advanced wound dressings, active wound care and antimicrobial dressings based on product type. Advanced wound dressings are sub-segmented into foam dressings, hydrocolloid dressings, Hydrofiber dressings, film dressings, alginate dressings, hydrogel dressings, collagen dressings whereas active wound care is sub-segmented into the artificial skin and skin substitutes and growth factors. On the basis of the type of wound, the market is segmented as chronic wounds and acute wounds. Chronic wounds are further segmented into diabetic foot ulcers, pressure ulcer, venous leg ulcer and arterial ulcer whereas acute wounds as burns, surgical and traumatic wounds. Based on the end user, the market is segmented into hospitals, home healthcare and others (private nursing home, pharmacies). Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/global-advanced-wound-care-management-market Advanced wound care segment contributed to largest share in 2015, however, active wound care segment will grow at fastest rate in the global market over the forecast period due to its effectiveness. Also, chronic wounds are more prevalent and will have the largest share in the market. North America represents developed regional markets for advanced wound care management and is expected to see the rapid growth in the years to come. The U.S. is by far the leading advanced wound care management market by country in North America. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to increase prevalence of chronic diseases such as diabetes, vascular diseases and the increase in aging population. Moreover, increasing expenditure in healthcare will also promote the growth of advanced wound care management market in this region. Europe was the second largest regional market and is expected to show significant growth in the years to come. This growth is mainly due to increase in the diabetic patient pool and geriatric population. Asia-Pacific is expected to witness noticeable growth in the near future. In Asia, China, India, and Japan will continue to be the fastest growing markets in advanced wound care management market. This growth in Asia Pacific market is attributed to the surge in the diabetic patient pool and large geriatric population base in countries like India and China. In Middle East & Africa; African region is projected to register low growth rate due the high cost of advanced wound care management. Latin America is another important regional market and is expected to experience moderate growth over the forecast period. Thus, all the aforementioned parameters are expected to propel the market growth in this region. Some of the key players in cancer drugs market include  Some of the key players in advanced wound care management market are 3M, Smith & Nephew plc., Acelity L.P. Inc., ConvaTec Inc., Medline Industries, Inc., Medtronic, Coloplast A/S, Organogenesis Inc. and Molnlycke Health Care. For more inquiry contact our sales team @ sales@zionmarketresearch.com This report segments the global advanced wound care management product market as follows: Global Advanced Wound Care Management Market: By Product Type Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.


News Article | November 22, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Tissue Engineering market is expected to grow from $6.24 billion in 2015 to reach $14.86 billion by 2022 with a CAGR of 13.2%. Growing usage of tissue engineering as an alternative for organs is the major factor propelling the market growth. In addition, recent technological advancements, encouraging government initiatives, and huge investments in R&D are the some of the key factors fostering the market growth. On the other hand, strict regulations for approvals, time taking process to develop a tissue & high costs are the constraints limiting the market growth. Access the complete report at: http://www.strategymrc.com/report/tissue-engineering-market Among all the applications, orthopedic segment leads the market globally with the biggest market share and is expected to grow with a higher CAGR during the forecast period. The growth of this segment is attributed to growing geriatric population and raising incidence of reconstructive and replacement surgeries. Neurology segment is likely to witness faster growth rate due to increasing research & development. North America is emerged as the major revenue generating region in the global market due to innovative technological developments, and increasing incidence of cancer rates in the Canada and U.S. Asia Pacific is expected to witness high growth rate during the forecast period. Some of the key players in global tissue engineering market include Acelity, CryoLife, ReproCell Inc., Stryker Corporation, Medtronic Inc., Integra LifeSciences, RTI Surgical Inc., Acell Inc, Organogenesis Inc, Zimmer Biomet, Athersys Inc, Sanofi, AastromBioSciences, BioMemetic Therapeutics, Tissue Regenix Group Plc, and Advanced Cell Technology. Request for a sample at: http://www.strategymrc.com/report/tissue-engineering-market Applications Covered: • Orthopedics, musculoskeletal and spine • Cardiology & vascular • Neurology • Dental • Cord blood & cell banking • GI & gynecology • Skin/integumentary • Urology • Cancer Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations


News Article | November 15, 2016
Site: www.newsmaker.com.au

Skin is the largest organ of the human body. It is composed of three layers: epidermis-the outermost layer; dermis-contains sweat glands, hair follicles and connective tissue and hypodermis-made up of fat and connective tissue. The main functions of the skin includes protection, sensation and regulation. The skin acts as a barrier and provides protection against harmful chemicals, radiation, microorganism and changing environmental conditions. It also helps regulate body temperature and maintain fluid balance. Skin is an extensive network of nerve cells and contains various receptors to detect changes in the environment such as touch, pain, heat and cold. Damage to skin due to burn or trauma can disrupt all the vital functions performed by the skin. Currently, topical antibiotics, skin grafting, wound dressings and tissue-engineered substitutes are available in the market that are used to treat skin-related disorders. A skin graft can be done by natural substitute such as amniotic membrane, potato peel or artificial material that includes synthetic polymer sheet, polymer foam or spray. These substitute helps in the healing process. Skin regeneration refers to the regrowth of the damaged skin from the remaining tissue. Stem cell therapy has a vital application in skin regeneration. Dermal regeneration matrix device provides an appropriate environment that is necessary for the proliferation and differentiation of skin cells. It helps in triggering the body‘s own repair mechanism by cell signaling, that drive the matrix environment in wound healing process. Dermal regeneration matrix device is used to treat skin burns and is also finds application in reconstructive surgery for contractures (scars). The dermal regeneration matrix device is placed over the damaged skin which provides an environment for regeneration of new skin and tissue. The matrix is made of cow collagen, silicone and shark cartilage. In 1996, the U.S. Food and Drug Administration (FDA) first approved integra dermal regeneration matrix device for treatment of burn injuries. In 2002, dermal regeneration matrix device was approved for use in reconstructive surgery for burn scars. About 30 million people in the U.S. are suffering from diabetes, of which 15% experience a diabetic foot ulcer in their lifetime. In January 2016, FDA approved the use of dermal regeneration matrix for treatment of chronic diabetic foot ulcers (DFU). The usage of dermal regeneration matrix device is expected to expand the growth of dermal regeneration matrix device owing to increase usage in chronic foot ulcer. Technological advancement and continued research in the development of artificial skin promises to bring more products to the marketplace. Increasing adoption of the device and long-term benefits associated with its application are some of the factors expected to fuel growth of the global dermal regeneration matrix device market over the forecast period. However, less awareness among the consumers and high cost of device are some of the key factors that could hamper growth of the market. On the basis of source, the global dermal regeneration matrix device market is segmented into cow collagen, silicone and shark cartilage. On the basis of end user, the global dermal regeneration matrix device market is segmented into hospitals and dermatology centers. The hospital segment is expected to contribute significantly to the total market in terms of market share. According to World Health Organization, over 265,000 deaths are caused due to burns each year. The majority of the burn cases occur in low and middle-income countries. Injuries such as traffic collisions, falls, burns, drowning, poisoning and others are expected to kills around five million people worldwide. Thus, the demand for dermal regeneration growth matrix is expected to be high in the low and middle-income countries over the forecast period. On the basis of region, the global dermal regeneration matrix device market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/12166 Some of the major players in the global dermal regeneration matrix device market include Integra LifeSciences Corporation, Platelet BioGenesis, Avita Medical, Stratatech, Organogenesis Inc., Smith & Nephew, Inc., ACell Inc., Symatese and others.


This report studies Wound Therapy Devices in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering  Acelity L.P., Inc.  Smith and Nephew Plc  Integra Lifesciences Corporation  Molnlycke Health Care  Convatec, Inc.  Coloplast Corp.  Organogenesis Inc.  Medline Industries, Inc.  MPM Medical Inc. Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Wound Therapy Devices in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Type I  Type II  Type III Split by application, this report focuses on consumption, market share and growth rate of Wound Therapy Devices in each application, can be divided into  Application 1  Application 2  Application 3 1 Wound Therapy Devices Market Overview  1.1 Product Overview and Scope of Wound Therapy Devices  1.2 Wound Therapy Devices Segment by Type  1.2.1 Global Production Market Share of Wound Therapy Devices by Type in 2015  1.2.2 Type I  1.2.3 Type II  1.2.4 Type III  1.3 Wound Therapy Devices Segment by Application  1.3.1 Wound Therapy Devices Consumption Market Share by Application in 2015  1.3.2 Application 1  1.3.3 Application 2  1.3.4 Application 3  1.4 Wound Therapy Devices Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Wound Therapy Devices (2011-2021) 2 Global Wound Therapy Devices Market Competition by Manufacturers  2.1 Global Wound Therapy Devices Production and Share by Manufacturers (2015 and 2016)  2.2 Global Wound Therapy Devices Revenue and Share by Manufacturers (2015 and 2016)  2.3 Global Wound Therapy Devices Average Price by Manufacturers (2015 and 2016)  2.4 Manufacturers Wound Therapy Devices Manufacturing Base Distribution, Sales Area and Product Type  2.5 Wound Therapy Devices Market Competitive Situation and Trends  2.5.1 Wound Therapy Devices Market Concentration Rate  2.5.2 Wound Therapy Devices Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion 3 Global Wound Therapy Devices Production, Revenue (Value) by Region (2011-2016)  3.1 Global Wound Therapy Devices Production and Market Share by Region (2011-2016)  3.2 Global Wound Therapy Devices Revenue (Value) and Market Share by Region (2011-2016)  3.3 Global Wound Therapy Devices Production, Revenue, Price and Gross Margin (2011-2016)  3.4 North America Wound Therapy Devices Production, Revenue, Price and Gross Margin (2011-2016)  3.5 Europe Wound Therapy Devices Production, Revenue, Price and Gross Margin (2011-2016)  3.6 China Wound Therapy Devices Production, Revenue, Price and Gross Margin (2011-2016)  3.7 Japan Wound Therapy Devices Production, Revenue, Price and Gross Margin (2011-2016)  3.8 Southeast Asia Wound Therapy Devices Production, Revenue, Price and Gross Margin (2011-2016)  3.9 India Wound Therapy Devices Production, Revenue, Price and Gross Margin (2011-2016) 4 Global Wound Therapy Devices Supply (Production), Consumption, Export, Import by Regions (2011-2016)  4.1 Global Wound Therapy Devices Consumption by Regions (2011-2016)  4.2 North America Wound Therapy Devices Production, Consumption, Export, Import by Regions (2011-2016)  4.3 Europe Wound Therapy Devices Production, Consumption, Export, Import by Regions (2011-2016)  4.4 China Wound Therapy Devices Production, Consumption, Export, Import by Regions (2011-2016)  4.5 Japan Wound Therapy Devices Production, Consumption, Export, Import by Regions (2011-2016)  4.6 Southeast Asia Wound Therapy Devices Production, Consumption, Export, Import by Regions (2011-2016)  4.7 India Wound Therapy Devices Production, Consumption, Export, Import by Regions (2011-2016) 7 Global Wound Therapy Devices Manufacturers Profiles/Analysis  7.1 Acelity L.P., Inc.  7.1.1 Company Basic Information, Manufacturing Base and Its Competitors  7.1.2 Wound Therapy Devices Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 Acelity L.P., Inc. Wound Therapy Devices Production, Revenue, Price and Gross Margin (2015 and 2016)  7.1.4 Main Business/Business Overview  7.2 Smith and Nephew Plc  7.2.1 Company Basic Information, Manufacturing Base and Its Competitors  7.2.2 Wound Therapy Devices Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 Smith and Nephew Plc Wound Therapy Devices Production, Revenue, Price and Gross Margin (2015 and 2016)  7.2.4 Main Business/Business Overview  7.3 Integra Lifesciences Corporation  7.3.1 Company Basic Information, Manufacturing Base and Its Competitors  7.3.2 Wound Therapy Devices Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 Integra Lifesciences Corporation Wound Therapy Devices Production, Revenue, Price and Gross Margin (2015 and 2016)  7.3.4 Main Business/Business Overview  7.4 Molnlycke Health Care  7.4.1 Company Basic Information, Manufacturing Base and Its Competitors  7.4.2 Wound Therapy Devices Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II


CANTON, Mass., Dec. 14, 2016 /PRNewswire/ -- Organogenesis Inc., a global leader in advanced wound care innovations and technologies, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned permanent Q-codes for its PuraPly™ and PuraPly Antimicrobial (AM)™...


Patent
Organogenesis Inc. | Date: 2011-06-21

Bioengineered collagen constructs with antimicrobial properties are provided. The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with an antimicrobial agent. The constructs are biocompatible. The present invention has a variety of applications, including wound dressing and surgical repair devices. Methods for treating a damaged or diseased soft tissue are provided. Methods for treating a wound in need of care and treatment are also disclosed.


Patent
Organogenesis Inc. | Date: 2012-01-25

Mastopexy and breast reconstruction prostheses and implantation method that allow for radiographic imaging of the breast tissue. The prostheses are arcuate and elongate optionally meshed to conform with breast tissue when implanted. Prostheses are made from naturally occurring extracellular matrix, primarily collagen, that, allows for mammographic imaging without interference as is expected from synthetic materials.


Patent
Organogenesis Inc. | Date: 2011-06-07

The invention is directed compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents are collected and incorporated into pharmaceutical or cosmetic preparations to treat an individual. The preparation is applied and has a rejuvenating effect on the cells and tissue.


Cultured tissue constructs comprising cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have morphological features and functions similar to tissues and their strength makes them easily handleable. Preferred cultured tissue constructs of the invention are prepared in defined media, that is, without the addition of chemically undefined components.


News Article | November 21, 2016
Site: www.prnewswire.com

CANTON, Mass., Nov. 21, 2016 /PRNewswire/ -- U.S. Representative Joe Kennedy III (MA-4) today visited the Canton, Mass. headquarters of Organogenesis Inc., a global leader in advanced wound care innovation and technologies, to tour its research and development labs and manufacturing...

Loading Organogenesis Inc collaborators
Loading Organogenesis Inc collaborators